Medical treatment and other combination regimens

MeSH terms

• Angiogenesis Inhibitors / administration & dosage
• Angiogenesis Inhibitors / therapeutic use
• Antineoplastic Agents, Alkylating / administration & dosage
• Antineoplastic Agents, Alkylating / adverse effects
• Antineoplastic Agents, Alkylating / pharmacokinetics
• Antineoplastic Agents, Alkylating / therapeutic use*
• Brain Neoplasms / drug therapy*
• Brain Neoplasms / secondary*
• Celecoxib
• Clinical Trials, Phase II as Topic
• Clinical Trials, Phase III as Topic
• Combined Modality Therapy
• Dacarbazine / analogs & derivatives
• Dacarbazine / therapeutic use
• Disease Progression
• Drug Resistance, Neoplasm
• Hematologic Diseases / chemically induced
• Humans
• Immunologic Factors / therapeutic use
• Immunotherapy
• Interferons / administration & dosage
• Interferons / therapeutic use
• Melanoma / drug therapy*
• Melanoma / secondary*
• Nitrosourea Compounds / administration & dosage
• Nitrosourea Compounds / adverse effects
• Nitrosourea Compounds / pharmacokinetics
• Nitrosourea Compounds / therapeutic use*
• Organophosphorus Compounds / administration & dosage
• Organophosphorus Compounds / adverse effects
• Organophosphorus Compounds / pharmacokinetics
• Organophosphorus Compounds / therapeutic use*
• Pyrazoles / administration & dosage
• Pyrazoles / therapeutic use
• Randomized Controlled Trials as Topic
• Skin Neoplasms / drug therapy*
• Sulfonamides / administration & dosage
• Sulfonamides / therapeutic use
• Survival Analysis
• Temozolomide
• Treatment Outcome